Oncolytics Reports Promising Survival Data With Pelareorep Combination

Oncolytics Biotech has reported updated clinical findings showing durable responses and encouraging survival observations with pelareorep combined with atezolizumab (Tecentriq) in patients with previously treated squamous cell anal cancer (SCAC). The findings from Cohort 4 of the Phase 1/2 GOBLET study highlight the potential of combining an investigational oncolytic immunotherapy with immune checkpoint inhibition.

The median duration of response (DOR) was approximately 15 months, compared with a historical benchmark of 9.5 months reported for retifanlimab monotherapy in a similar patient population. Median overall survival (OS) had not been reached at the time of the analysis. All patients who responded to the combination survived beyond 12 months, with several surviving for more than 24 months.

The findings are encouraging in advanced anal cancer, where more than 90% of cases are associated with human papillomavirus (HPV). However, the response-duration estimate is based on company calculations, and the historical comparison does not establish that the combination is superior to checkpoint inhibitor monotherapy.

Earlier Response Data Provide Clinical Context

In an earlier analysis of the second-line SCAC population, Oncolytics reported an objective response rate (ORR) of 30% among 20 evaluable patients treated with pelareorep and atezolizumab. The median DOR was reported as 15.5 months, compared with 9.5 months for retifanlimab in historical data.

These earlier findings provide context for the latest update, which emphasizes response durability and survival among responders. The results should nevertheless be interpreted cautiously because the combination has not been compared directly with retifanlimab in a randomized trial. Differences in patient characteristics, study design and follow-up can affect comparisons between separate studies.

Pelareorep and Checkpoint Inhibition

Pelareorep is an investigational, intravenously administered oncolytic reovirus designed to replicate selectively in tumour cells while activating innate and adaptive antitumour immune responses. Its proposed immune effects include inflammatory cytokine activity, tertiary lymphoid structure formation and expansion of tumour-infiltrating lymphocytes.

Atezolizumab is a programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor. The combination is intended to investigate whether virus-mediated immune activation can complement checkpoint inhibition and support antitumour activity.

The GOBLET study evaluates pelareorep-based combinations across five treatment groups involving advanced gastrointestinal cancers. These include pancreatic cancer, different treatment settings of metastatic colorectal cancer, and advanced unresectable anal cancer. Cohort 4 evaluates pelareorep plus atezolizumab in patients with second-line or later SCAC.

The study’s co-primary endpoints include objective response rate and/or disease control rate, alongside safety. Additional efficacy assessments and biomarker analyses are included as secondary or exploratory endpoints.

FDA Fast Track Designation and Development Plans

Oncolytics reported that recent interactions with the U.S. Food and Drug Administration (FDA), together with Fast Track Designation, have helped clarify its potential development strategy for pelareorep in anal cancer.

The company plans to explore additional clinical studies with a potential checkpoint inhibitor partner to support registrational development. Oncolytics believes that durable responses could support consideration of an accelerated approval pathway, while additional survival evidence could contribute to establishing clinical benefit for potential full approval.

These remain proposed regulatory strategies rather than established approval outcomes. Further clinical evidence and agreement with the FDA will be necessary to determine the appropriate development pathway.

Potential Expansion Into HPV-Associated Head and Neck Cancer

Oncolytics is also exploring the potential of pelareorep in other HPV-associated malignancies, particularly head and neck squamous cell carcinoma (HNSCC). HPV is associated with approximately 70% of oropharyngeal cancers in the United States.

Pelareorep has previously shown signals of antitumour activity in head and neck cancer studies. However, the combination with a checkpoint inhibitor has not yet been evaluated in this disease, and the company may explore a combination study as part of its broader development strategy.

This expansion remains exploratory. The anal cancer findings do not establish efficacy in head and neck cancer, and further studies would be needed to assess the combination in that setting.

Clinical Significance

The updated GOBLET Cohort 4 findings highlight a potentially important signal of response durability with pelareorep plus atezolizumab in previously treated anal cancer. The approximately 15-month median DOR and survival beyond one year among all responding patients support continued investigation of the combination.

However, median OS remains unreached, and survival observations among responders do not establish a survival benefit across all treated patients. Further clinical evaluation will be needed to confirm the findings, characterize the combination’s safety and efficacy, and determine its potential regulatory role. Expansion into other HPV-associated cancers will require separate clinical evidence.

 Reference

Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers, Oncolytics, 27 October 2026

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations with Pelareorep and Atezolizumab (GOBLET), ClinicalTrials.gov ID NCT07280377